Profile data is unavailable for this security.
About the company
Telo Genomics Corp. is a molecular diagnostics company that is engaged in developing the telomere analysis platform Teloview to enable the development of diagnostic and prognostic applications based on the quantification of genomic instability as a disease predictor. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. It quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.71m
- Incorporated2011
- Employees8.00
- LocationTelo Genomics CorpMars Centre, 101 College St Suite 200TORONTO M5G 1L7CanadaCAN
- Phone+1 (416) 673-8487
- Fax+1 (204) 582-0922
- Websitehttps://www.telodx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appili Therapeutics Inc | 212.30k | -2.53m | 2.57m | 7.00 | -- | -- | -- | 12.12 | -0.0209 | -0.0209 | 0.0018 | -0.1287 | 0.1839 | -- | 0.786 | -- | -219.60 | -143.75 | -- | -1,382.22 | -- | -- | -1,194.04 | -2,076.82 | -- | -2.80 | -- | -- | -87.86 | -12.79 | 30.58 | -- | 16.92 | -- |
| Rakovina Therapeutics Inc | 0.00 | -8.36m | 3.39m | -- | -- | 1.79 | -- | -- | -0.5705 | -0.5705 | 0.00 | 0.0893 | 0.00 | -- | -- | -- | -158.14 | -- | -221.29 | -- | -- | -- | -- | -- | -- | -21.46 | 0.579 | -- | -- | -- | -55.86 | -- | -- | -- |
| XORTX Therapeutics Inc | 0.00 | -2.64m | 3.98m | 3.00 | -- | 1.11 | -- | -- | -0.6433 | -0.6433 | 0.00 | 0.5153 | 0.00 | -- | -- | -- | -58.35 | -39.11 | -94.63 | -43.59 | -- | -- | -- | -- | -- | -- | 0.0291 | -- | -- | -- | -53.53 | -- | 48.96 | -- |
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.83m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1226 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0177 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Telo Genomics Corp | 0.00 | -2.71m | 5.03m | 8.00 | -- | -- | -- | -- | -0.0289 | -0.0289 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -517.19 | -98.53 | -51,970.82 | -111.33 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2116 | -- | -- | -- |
| Quest PharmaTech Inc | 0.00 | -96.59k | 5.09m | 0.00 | -- | 0.2198 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.1365 | 0.00 | -- | -- | -- | -0.398 | 10.66 | -0.4181 | 11.12 | -- | -- | -- | -- | -- | -- | 0.0415 | 0.00 | -- | -- | 40.32 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| CATAM Asset Management AGas of 31 Dec 2025 | 400.00k | 0.40% |
